This increased propensity to coexpress p16 and ERG‐positive PCa in AA patients in part compensate for the lower fraction of ERG‐positive cancers to make the EA and AA PCa more equal in p16 expression. The gene discussed is CDKN2A; the disease is posterior cortical atrophy.